Studying immune cells in chronic GVHD after stem cell transplant
Part of Immune system & allergy clinical trials.
This study looks at immune cells in the blood and tissues of people who have had a stem cell transplant. It aims to understand chronic graft-versus-host disease (GVHD), a common complication, so doctors can better detect and treat it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had a stem cell transplant from another person.
- You are age 7 or older and weigh at least 30 kg (66 pounds) if under 18.
- You are willing to give blood, stool, saliva, and cheek swab samples.
- You have been diagnosed with chronic GVHD (or you have had a transplant even without GVHD).
- You are not pregnant or nursing.
- You are able to make your own decisions about joining the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (vedolizumab, cyclophosphamide, and tacrolimus) to prevent graft-versus-host disease, a common complication after a donor stem cell transplant. It is for people with certain blood cancers who are getting a reduced-intensity transplant.
This Phase 1 study tests a new combination of medicines to prevent graft-versus-host disease (GVHD) after an allogeneic stem cell transplant. If it works well, it may lower the chance and severity of GVHD, which can affect skin, liver, and the gut.
This trial tests a new way to prevent graft-versus-host disease (GvHD), a common complication after a stem cell transplant. It is for people with certain blood cancers who are getting a stem cell transplant from a half-matched family member or unrelated donor.
This trial tests adding ruxolitinib to standard drugs (tacrolimus and methotrexate) to prevent graft-versus-host disease in children and young adults undergoing a stem cell transplant for acute leukemia or myelodysplastic syndrome. The goal is to lower the risk of GVHD and improve transplant outcomes.
This study looks at immune cells in tissues affected by chronic graft-versus-host disease (cGVHD), a common complication after a stem cell transplant. It aims to better understand the condition, which may lead to better treatments.
This study follows patients who have had a stem cell transplant and developed chronic graft-versus-host disease (a condition where transplanted cells attack the body). Researchers will track your symptoms and collect blood samples to understand what affects how well patients do over time.
Hear when a new Graft Versus Host Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.